Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis

By Starakis I.   Gogos C.A.   Bassaris H.  

International Journal of Antimicrobial Agents, Vol. 23, Iss. 2, 2004-02 ,pp. : 129-137

Elsevier

Access to resources Recommend Favorite

Efficacy and Tolerability of Moxifloxacin in 2338 Patients with Acute Exacerbation of Chronic Bronchitis

By Barth J.  

Clinical Drug Investigation, Vol. 23, Iss. 1, 2003-01 ,pp. : 1-10

Adis International

Access to resources Recommend Favorite

Pharmacokinetic and Pharmacodynamic Aspects of Oral Moxifloxacin 400 mg/day in Elderly Patients with Acute Exacerbation of Chronic Bronchitis

By Pea Federico  

Clinical Pharmacokinetics, Vol. 45, Iss. 3, 2006-01 ,pp. : 287-295

Adis International

Access to resources Recommend Favorite

A Multinational, Multicentre, Non-blinded, Randomized Study of Moxifloxacin Oral Tablets Compared with Co-amoxiclav Oral Tablets in the Treatment of Acute Exacerbation of Chronic Bronchitis

By Schaberg T   Ballin I   Huchon G   Bassaris H   Hampel B   Reimnitz P    

The Journal of International Medical Research, Vol. 29, Iss. 4, 2001-07 ,pp. : 314-328

Field House Publishing

Access to resources Recommend Favorite

Treatment Outcomes in Acute Exacerbations of Chronic Bronchitis: Comparison of Macrolides and Moxifloxacin from the Patient Perspective

By Lorenz J   Thate-Waschke I-M   Mast O   Kubin R   Rychlik R   Pfeil T   Daniel D   Tillotson GS  

The Journal of International Medical Research, Vol. 29, Iss. 2, 2001-03 ,pp. : 74-86

Field House Publishing

Access to resources Recommend Favorite